Drug intelligence / Profile preview

TQB3911

Development stage: Phase 1
Lead developer: Chia Tai-Tianqing Pharmaceutical Group
Modality: Small Molecules
Administration: Oral

Overview

TQB3911 is a small molecule BCR::ABL1 allosteric inhibitor developed for the treatment of BCR::ABL fusion gene-positive leukemia, including chronic myeloid leukemia. It acts by occupying the myristyl binding site of the BCR::ABL1 fusion protein, thereby restoring inhibition of its kinase activity and ultimately suppressing tumor cell proliferation. TQB3911 is currently in Phase 1 clinical trials to evaluate its safety, tolerability, and initial efficacy in patients with BCR::ABL-positive leukemias[2][3][4][6].

Targets

ABL1 (ABL proto-oncogene 1, non-receptor tyrosine kinase)

Beyond the preview

Go deeper on TQB3911.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TQB3911.

Explore the full profile